Touchlight Ranked Number Four Fastest Growing Technology Company in the UK in the 2021 Deloitte Technology Fast 50
Published: 22 November 2021
Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, today announced that it ranked number 4 in the 2021 Deloitte UK Technology Fast 50, a ranking of the 50 fastest-growing technology companies in the UK. Rankings are based on percentage revenue growth over the last four years. Touchlight grew 11,421 per cent during this period.
“This recognition is a confirmation of our vision that DNA will underpin the future of healthcare. Our technology allows faster, smoother and more reliable development of genetic medicines. It is a category that had not been widely known until recently but which has underpinned a major leap forward in medicine development. Cell- and gene therapies, mRNA and DNA vaccines all rely on DNA, and we believe that Touchlight’s dbDNA will become a core component for such advanced therapies, transforming lives and patient access.”
Jonny Ohlson, Touchlight’s Executive Chairman
“The extraordinary growth of this year’s Fast 50 represents the remarkable tenacity of the UK’s technology industry. Deloitte’s 2021 Fast 50 awards are a clear demonstration of the wealth of talent, creativity, and entrepreneurship in the UK’s technology industry today.
The 50 fastest growing UK technology companies, as ranked by Deloitte, generated around £2.92bn in total annual revenues in the year 2020/21 and employed more than 19,320 people. The Deloitte UK Technology Fast 50 recorded an average three-year growth rate of 3,337 per cent.”
Duncan Down, lead partner for the Deloitte UK Technology Fast 50 programme
About Touchlight
Touchlight is an innovation-driven leading CDMO pioneering enzymatic GMP DNA production to enable the genetic medicine revolution. As pioneers, with an FDA Drug Master File accepted in 2022 followed in 2025 with the world’s first cell-free DNA GMP license, Touchlight’s enzymatic DNA technology is on the cutting edge of AAV, mRNA, DNA vaccine, and gene editing technology with its state-of-the-art facility recognised by ISPE’s Facility of the Year Awards (FOYA) for Innovation.
With multiple client products already in the clinic, Touchlight’s evidence-based, synthetic DNA manufacturing solutions offer a scalable, sustainable alternative to plasmid DNA (pDNA) for all stages of pre-clinical, clinical and commercial development. The company and technology are built on the conviction that DNA is fundamental to the future of medicine. Traditional methods, based on bacterial fermentation, are slow, costly, and unable to meet the growing demands of genetic medicine due to limited scalability and speed. Founded in 2007, Touchlight’s team is inspired by breakthroughs in genetic medicine, recognising the urgent need for innovative DNA production techniques to support the future of genetic therapies.
For more information please contact:
Karen Fallen, Chief Executive Officer
Verna McErlane, Chief Commercial Officer
E: info@touchlight.com
T: +44 20 8481 9200
Get all the latest updates
No spam. Just interesting articles, and exclusive updates in your inbox every week.
